Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin and Alkali Therapy in ADPKD
NCT05870007Phase 2Enrolling by invitation
- Sponsor
- Taipei Medical University Shuang Ho Hospital
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin and sodium bicarbonate in autosomal dominant polycystic kidney disease (ADPKD) (3 arms), sponsored by Taipei Medical University Shuang Ho Hospital. Primary endpoints: Changes in kidney function at 12 months, Changes in liver function at 12 months and 3 more. Started May 2023; status: enrolling by invitation.
02
Drugs
atorvastatinsodium bicarbonate
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT05870007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870007.